Objective To investigate the current research status of ferroptosis in Parkinson disease in recent years. Methods CiteSpace was used to perform bibliometric and visual analyses of the articles on the mechanism of action of ferroptosis in Parkinson disease and related prevention and treatment measures in CNKI and Web of Science （WoS）. Results A total of 92 articles from CNKI and 273 articles from WoS were included in this study. There was a tendency of increase in the number of articles published in China and globally. In CNKI， the keywords of ferroptosis， Parkinson's disease， oxidative stress， and traditional Chinese medicine were cited for many times， while in WoS， activation， cell death， alpha-synuclein， and Parkinson disease were cited for many times. There were 7 clusters of keywords in CNKI and 12 clusters in WoS. The top 5 authors （teams） in terms of the number of publications in CNKI were Yang Xinling； Zhang Lijie； Li Shaodan； Hao Mengdie； and Lu Ranran， while the top 5 authors （teams） in WoS were Ayton， Scott； Zhu， Meiling； Qu， Le； Devos， David； and Xie， Junxia. The number of team members in China was lower than that in foreign countries， mainly small team cooperation. As for the number of articles published by institutional cooperation， Qingdao University published the highest number of articles in CNKI， while the University of Melbourne published the highest number of articles in WoS. Biochemistry was the subject with the highest frequency， and there were intersections between disciplines. China was the core representative of state cooperation with the highest frequency. Conclusion The research on the association between Parkinson disease and ferroptosis mainly focuses on oxidative stress， neuroprotection， traditional Chinese medicine， and neuroinflammation， among which neuroprotection and neuroinflammation are the latest trends for development. Therefore， there may be more targeted therapies for neuroinflammation and therapies that stimulate neuroprotection in the future to alleviate pain and improve the quality of life of patients.
Parkinson Disease

Objective:To explore the implementation of standardized preventive nursing training for venous thromboembolism (VTE) based on the analyze, design, development, implement and evaluation model (ADDIE model), and evaluate the effectiveness of the training.Methods:From September 2021 to December 2022, a special training group was established. The specialized training courses were designed and developed guided by the "National Medical Quality and Safety Improvement Goals", based on the ADDIE model, combined with literature research and Delphi expert consultation. In May 2023, 20 thrombosis liaison nurses from 16 ClassⅢ Grade A hospitals across the country were trained on VTE standardized preventive nursing. After training, the Kirkpatrick evaluation method was used to evaluate the training effectiveness from the aspects of nurse satisfaction with the training, knowledge and skills, implementation of key job technologies, and organizational satisfaction.Results:The satisfaction of thrombosis liaison nurses with the training objectives, content, methods, and teachers of VTE standardized preventive nursing training based on the ADDIE model was all 100%. Compared with before training, there was a statistically significant improvement in the theoretical, operational, and overall scores of thrombosis liaison nurses after training ( P<0.05). In terms of the implementation of key technologies for the position, the execution rate of the thrombosis liaison nurse returning to the unit for retraining other personnel was 90%, with a total of 516 nurses receiving training. After training, the theoretical, operational, and overall scores of the 351 nurses who participated in pre-and post training assessments all improved compared to before training, with statistically significant differences ( P<0.05) . Conclusions:VTE standardized preventive nursing training based on the ADDIE model can effectively improve the comprehensive capacity of nurses in VTE prevention, and nurses have a high recognition of the training program.

Objective:To evaluate the clinical value of Xing's ureteroileal anastomosis technique in radical cystectomy.Methods:The data of 38 patients who underwent radical cystectomy with Xing's ureteroileal anastomosis technique at Cancer Hospital, Chinese Academy of Medical Sciences and Beijing Chaoyang Hospital from July 2013 to June 2021 were retrospectively reviewed. There were 30 males and 8 females. The mean age was 61.6±15.1 years old. The mean body mass index (BMI) was 25.1±2.7 kg/m 2. The American Society of Anesthesiology (ASA) graded 25 cases as grade 1, 10 cases as grade 2 and 3 cases as grade 3. There were 35 cases with stage cT 2N 0M 0 and 3 cases with cT 3N 0M 0. All patients underwent radical cystectomy and ileal conduit, and the ureteroileal anastomosis was performed using the Xing's ureteroileal anastomosis technique. Afferent loop entry was divided equally into two lumens. After 1.5 cm-long lengthwise incisions, each ureter was directly and end-to-end anastomosed to the aforementioned lumens. Postoperative information was recorded, including ureteric stricture, ureteric reflux, hydronephrosis, anastomotic leakage, renal calculus, urinary tract infection, and pyelonephritis. Results:Ureteroileal anastomosis was performed successfully in 38 cases with 76 units. The median follow-up time was 35.6 (17.0, 46.3) months. Three patients developed unilateral anastomotic stenosis after operation. Five patients had unilateral ureteral reflux. Two patients had unilateral hydronephrosis. No anastomotic leakage, urinary tract infection, or pyelonephritis occurred after the operation. Renal calculus appeared in 3 cases, all on the left unit.Conclusions:Xing's ureteroileal anastomosis technique is a simple method with few postoperative and good functional outcomes.

Objective: To evaluate the prognostic value of kinetic changes in minimal residual disease (MRD) status, as well as its relationship with risk stratification, therapeutic response and treatment in patients with newly-diagnosed multiple myeloma (MM) . Methods: A total of 135 patients with newly-diagnosed MM were screened, and 105 patients who achieved VGPR or more as the best responses were included into this study. The MRD status was determined by multiparameter flow cytometry (MFC) at multiple intervals after two cycles of treatment until clinical relapse, death, or last follow-up. The statistical methods included Kaplan-Meier analysis, Cox regression, etc. Results: ①In all 135 patients, 57.8% (78/135) patients achieved MRD negativity (MRD^-) after treatment. In 105 patients who achieved VGPR and thus included in this study, the MRD^- rate was 72.4% (76/105) , with a median interval of 3 months from starting treatment to achievement of MRD^- status. ②The 2-year PFS rate of patients with MRD^- status was significantly higher than that of MRD⁺ status (62.2% vs 41.3%, P=0.001) , while MRD persistence (MRD⁺) was an independent factor for poor prognosis (multivariate analysis for PFS: P=0.044, HR=3.039, 95%CI 1.029-8.974) . ③Loss of MRD^- status (i.e., MRD reappearance) showed inferior outcomes compared with MRD sustained negative ones, the PFS was 18 months versus not reach (P<0.001) and the OS was not reach for both (P=0.002) . ④The 2-year PFS and OS rates of patients with duration of MRD^-status≥12 months were significantly higher than those of the control group (PFS: 77.7% vs 36.7%, P<0.001; OS: 96.4% vs 57.9%, P<0.001 respectively) . Duration of MRD^- status was associated with a marked reduction in risk of relapse or death (univariate analysis for PFS: P<0.001, HR=0.865, 95%CI 0.815-0.918; for OS: P=0.001, HR=0.850, 95%CI 0.741-0.915 respectively) . ⑤Moreover, even in patients carrying high-risk cytogenetic abnormalities (CA) or ineligible for ASCT, MRD negativity remained its prognostic value to predict PFS (high-risk CA medianPFS: not reach vs 19 months, P=0.006; ineligible for ASCT medianPFS: not reach vs 25 months, P=0.052 respectively) . ⑥Last, treatment with the bortezomib-based regimens contributed to prolonged MRD^- duration (median MRD^- duratio: 25 months vs 10 months, P=0.034) . Conclusion Our findings supported MRD⁺ status as an independent poor prognostic factor in MM patients, which implicated that duration of MRD^- status also played a significant role in evaluation of prognosis, while loss of MRD^-status might serve as an early biomarker for relapse. Therefore, monitoring of MRD kinetics might more precisely predict prognosis, as well as guide treatment decision, especially for when to start retreatment in relapsed patients.

Objective: To investigate the efficacy and safety of IA regimen which contains idarubicin (IDA) 8 mg/m², 10 mg/m² or 12 mg/m² as induction chemotherapy for adult patients with de-novo acute myeloid leukemia (AML) . Methods: A total of 1 215 newly diagnosed adult AML patients, ranging from May 2011 to March 2015 in the First Affiliated Hospital of Soochow University and other 36 clinical blood centers in China were enrolled in the multicenter, single-blind, non-randomized, clinical controlled study. To compare the response rate of complete remission (CR) , adverse events between different dose idarubicin combined with cytarabine (100 mg/m²) as induction chemotherapy in newly diagnosed patients of adult AML. Results: Of 1 207 evaluable AML patients were assigned to this analysis of CR rate. The CR rates of IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 73.6% (215/292) , 84.1% (662/787) and 86.7% (111/128) , respectively (P<0.001) . After adjusted for age, blast ratio of bone marrow, FAB classification and risk stratification, the odds ratios (95% CI) of IDA 10 mg/m² group and IDA 12 mg/m² group were 0.49 (0.34-0.70) and 0.36 (0.18-0.71) , as compared with the IDA 8 mg/m² group (P<0.001, P=0.003) . In the intermediate and favorable groups, CR rates was 76.5% (163/213) , 86.9% (506/582) and 86.1% (68/79) in different doses of IDA (P=0.007) . Interestingly, IA regimen with IDA 10 mg/m² was the only beneficial factor affecting CR in this group after adjusted for age, blast ratio of bone marrow and FAB classification[OR=0.47 (95% CI 0.31-0.71) , P<0.001]. CR rates in adverse group was 50.0% (18/36) , 60.6% (43/71) and 81.8% (18/22) respectively (P=0.089) . However, the odds ratios (95% CI) of IDA 12 mg/m² when compared with the IDA 8 mg/m² was 0.22 (0.06-0.80) , after adjusted for age, blast ratio of bone marrow and FAB classification. The median time (days) of neutrophil count less than 0.5×10⁹/L in IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 14 (11-18) , 15 (11-20) and 18 (14-22) , respectively (P=0.012) and of platelet count lower than 20×10⁹/L were 14 (7-17) , 15 (11-20) and 17 (15-21) , respectively (P=0.001) . The incidences of lung infection in the three groups were 9.8%, 13.5% and 25.2%, respectively (P<0.001) . Conclusions For young adult patients (aged 18-60 years) with AML in China, intensifying induction therapy with idarubicin 10 mg/m² is clinically superior to IDA 8 mg/m² and IDA 12 mg/m² in favorable intermediate AML subgroup. However, idarubicin 12 mg/m² is more suitable to adverse AML subgroup.

OBJECTIVETo explore the effect of heat shock protein 90 (HSP90) inhibitor (17-DMAG) and oxaliplatin on the proliferation and invasion of colorectal cancer.

METHODSAfter 17-DMAG, oxaliplatin and half-dose combination of 2 drugs processing colorectal cancer SW480 and HCT116 cell lines, CCK8 assay was applied to detect cell viability. RT-PCR and Western blot were used to detect the expression level of the apoptosis-related molecules. Transwell chemokine axis experiment and Western blot were employed to detect cell invasion ability and the expression level of tumor metastasis-associated protein.

RESULTSThe growth of SW480 and HCT116 cells was inhibited after the administration of 17-DMAG and oxaliplatin(P<0.05) in dose- and time-dependent manner. Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs. Transwell chemokine axis experiments showed the penetrating relative percentage and expression level of MMP9 and integrin β3 decreased, especially for half-dose combination of 2 drugs.

CONCLUSION17-DMAG and oxaliplatin can co-inhibit the proliferation and invasion of colorectal cancer.

Antineoplastic Agents ; Apoptosis ; Benzoquinones ; Cell Proliferation ; Cell Survival ; Colorectal Neoplasms ; HCT116 Cells ; Humans ; Lactams, Macrocyclic ; Neoplasm Invasiveness ; Organoplatinum Compounds

Objective To investigate the diagnostic significance of basophil activation test (B A T) in ana-phylaxis to non-ionic contrast media through testing the content of CD 63, m ast cell-carboxypeptidase A 3 (M C-CPA 3), and term inal com plem ent com plex SC5b-9 of the individuals by testing their levels in the norm al im m une group and the anaphylaxis groups to β-lactam drugs and non-ionic contrast media. Methods The CD 63 expression of basophilic granulocyte in blood w as detected by flow cytom etry. The levels of M C-CPA 3 in blood serum and SC5b-9 in blood plasm a w ere detected by ELISA . Results The CD 63 expression of basophilic granulocyte in blood, the levels of M C-CPA 3 and SC5b-9 of anaphylaxis to non-ionic contrast media and β-lactam drugs w ere significantly higher than that in norm al im m une group (P<0.05). Conclusion There is activation of basophilic granulocytes, m ast cells and com plem ent system in anaphylaxis to non-ionic contrast media. B A Tcan be used to diagnose the anaphylaxis to non-ionic contrast media.

ObjectiveTo evaluate the curative effect of supplementedGanmai-Dazaodecoction for malignant tumor correlation with depression.MethodsA total of 98 patients with malignant tumor-related depression were divided into a treatment group and acontrol group according to the random number table. The control group were treated with flupentixol and melitracen tablets (Deanxit) combined with conventional treatment, the treatment group were treated with oral administration of traditional Chinese medicine supplemented Ganmai-Dazaodecoction combined with conventional treatment for 8 weeks. The Hamilton Depression Scale (HAMD) was used to evaluate the curative effect.ResultsThe effective rate showed no significant difference between the treatment groupand the control group (79.59%vs.75.51%;χ2=0.059,P=0.809). HAMD scores in both groups were significantly decreased after the treatment than before treatment (12.8±3.4 vs. 29.4±4.7 in the treatment group, 12.3±3.6vs.28.7±4.5 in the controlgroup, allP<0.05), there was no significant difference in HAMD scores after the treatment between the treatment group and the control group (t=0.707,P=0.481). ConclusionCurative effect of supplementedGanmai-Dazaodecoction is equal to flupentixol andmelitracen tablets in patients with malignant tumor-related depression.

Objective To explore the effect of heat shock protein 90 (HSP90) inhibitor (17-DMAG) and oxaliplatin on the proliferation and invasion of colorectal cancer. Methods After 17-DMAG, oxaliplatin and half-dose combination of 2 drugs processing colorectal cancer SW480 and HCT116 cell lines, CCK8 assay was applied to detect cell viability. RT-PCR and Western blot were used to detect the expression level of the apoptosis-related molecules. Transwell chemokine axis experiment and Western blot were employed to detect cell invasion ability and the expression level of tumor metastasis-associated protein. Results The growth of SW480 and HCT116 cells was inhibited after the administration of 17-DMAG and oxaliplatin (P<0.05) in dose- and time-dependent manner. Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs. Transwell chemokine axis experiments showed the penetrating relative percentage and expression level of MMP9 and integrin β3 decrease d, especially for half-dose combination of 2 drugs. Conclusion 17-DMAG and oxaliplatin can co-inhibit the proliferation and invasion of colorectal cancer.

Objective To explore the effect of heat shock protein 90 (HSP90) inhibitor (17-DMAG) and oxaliplatin on the proliferation and invasion of colorectal cancer. Methods After 17-DMAG, oxaliplatin and half-dose combination of 2 drugs processing colorectal cancer SW480 and HCT116 cell lines, CCK8 assay was applied to detect cell viability. RT-PCR and Western blot were used to detect the expression level of the apoptosis-related molecules. Transwell chemokine axis experiment and Western blot were employed to detect cell invasion ability and the expression level of tumor metastasis-associated protein. Results The growth of SW480 and HCT116 cells was inhibited after the administration of 17-DMAG and oxaliplatin (P<0.05) in dose- and time-dependent manner. Processed by 17-DMAG 100 nmol/L, oxaliplatin 50 mg/L and half-dose combination of 2 drugs, transcription level of the apoptosis inhibitory gene (Bcl-2) in SW480 and HCT116 cells was decreased, the level of apoptosis promoting gene (Bax) transcription and protein PARP-1 spliceosome expression was increased, and the above trend was more obvious when using half-dose combination of 2 drugs. Transwell chemokine axis experiments showed the penetrating relative percentage and expression level of MMP9 and integrin β3 decrease d, especially for half-dose combination of 2 drugs. Conclusion 17-DMAG and oxaliplatin can co-inhibit the proliferation and invasion of colorectal cancer.